From fear to sight: new frontiers in brain technology. Published November 3, 2026 A mouse navigating an experimental arena, an implant designed to generate visual perception, and a device that adjusts Parkinson's treatment might appear to have little in common. Together, however, they illustrate three capabilities shaping neurotechnology: observing brain activity, interpreting its meaning, and using electrical stimulation to influence what happens next. Each addresses a different challenge. Researchers at McGill University and the University of Toronto Scarborough are investigating how the brain represents danger. Neuralink is developing Blindsight to deliver visual information through an implant. Medtronic already offers adaptive deep brain stimulation that responds to patients' brain signals. These developments sit at different stages of scientific and commercial maturity. Viewed together, they reveal where the field is progressing and why better hardware alone cannot guarantee better outcomes. The opportunity lies in connecting what a device can measure or stimulate with something that improves a person's everyday life. Brain imaging reveals how fear memories overlap. A study published in Nature Neuroscience examined how threatening and neutral environments are represented in two parts of the hippocampus, a brain region involved in memory.[1] Researchers compared the dorsal and ventral CA1 regions as mice transitioned between the environments. According to McGill's account of the fear-memory experiments, an augmented reality arena changed sights and sounds while miniature microscopes recorded neuronal activity. This allowed researchers to observe transitions between memory representations as they happened. The study found that threatening and neutral representations became more similar in ventral CA1 after fear learning, while remaining distinct in dorsal CA1. Ventral CA1 also reinstated the threatening representation faster and more strongly. Key Comparisons From the Fear-Memory Study | Observation | Dorsal CA1 | Ventral CA1 | | Change After Fear Conditioning | Representations changed | Larger changes, scaling with freezing | | Threatening Versus Neutral Representations | Remained distinct during testing | Were more similar during testing | | Threatening Memory Retrieval | Slower and weaker by comparison | Faster and stronger | The researchers suggest that overlapping representations may allow faster transitions into threat-related memories. McGill frames this as a potential survival tradeoff: responding quickly can matter more than distinguishing every situation perfectly. That offers a possible avenue for understanding trauma-related fear, but the experiments involved mice and did not test a PTSD treatment. The broader technological lesson is that observing when a brain state changes can be as informative as identifying where activity occurs. Timing may help researchers ask more precise questions about future interventions. Neuralink Blindsight aims to generate visual perception. Blindsight approaches the brain from another direction. Rather than observing a naturally occurring response, Neuralink wants to deliver information that the brain can interpret as vision. On its visual prosthesis development page, Neuralink describes a camera capturing the surrounding environment and an implant activating brain areas responsible for visual function. The aim is to bypass damage affecting the normal pathway from the eyes to the brain. This distinction matters. A system that records signals to control a cursor translates activity out of the brain. A visual prosthesis must translate information into stimulation that produces useful perception. Success in one direction does not automatically establish success in the other. Neuralink reports that Blindsight has received FDA Breakthrough Device Designation, while its website invites people to register for future visual-prosthesis trials. The designation supports development and regulatory review; it does not establish that the device is approved for commercial use or has restored useful vision in humans. Useful vision requires more than detectable stimulation. The practical questions extend beyond whether stimulation produces a sensation. Can a person distinguish an obstacle from an opening? Recognize an object? Use the information consistently outside a controlled setting? Those are examples of functional outcomes that would help establish value. An engineering demonstration and an improvement in daily independence answer different questions. Miniaturization remains important. Securities.io's coverage of ultra-thin brain-computer interfaces provides background on efforts to reduce implant size and improve communication. Yet increasingly capable hardware still needs evidence showing that the information it delivers is useful to the recipient. Adaptive brain stimulation brings feedback into treatment. Medtronic provides a clinical example of sensing and stimulation operating together. In February 2025, the company announced FDA approval of BrainSense Adaptive deep brain stimulation for people with Parkinson's disease. Deep brain stimulation uses implanted electrodes to deliver electrical stimulation to targeted brain regions. The adaptive feature adjusts stimulation based on recorded brain activity, allowing therapy to respond as signals change. Think of the distinction between a heating system operating on a fixed schedule and one responding to a thermostat. The analogy is imperfect, but it explains feedback: the system measures a condition and changes its output accordingly. Medtronic's adaptive stimulation technology operates within clinician-managed treatment. Clinicians program therapy and evaluate outcomes. It is intended to help manage Parkinson's symptoms, and measurable signals may not be available in every patient. This supplies an important reference point for the wider field. Neurotechnology can produce value through a narrowly defined therapeutic task. Automatically adjusting an established treatment may be less spectacular than restoring a lost sense, but it represents a concrete application of brain-responsive medicine. What separates a discovery from a useful neurotechnology. The three examples should not be interpreted as successive steps toward one universal brain device. They involve different brain regions, objectives, and evidence requirements. Their shared challenge is translating neural activity into information that supports a useful action. The McGill study illustrates the challenge of interpretation. A pattern associated with fear does not, by itself, reveal whether changing that pattern would safely improve symptoms. Blindsight illustrates the challenge of encoding information. A stimulation pattern must become meaningful to its recipient. Adaptive stimulation illustrates feedback within a defined clinical application. Readers evaluating future announcements can ask three practical questions: * What has been demonstrated: a measurable signal, a laboratory task, or a meaningful patient benefit? * How reliably does the result persist across time, settings, and participants? * What surgery, training, maintenance, and clinical support are required? These questions also sharpen the investment analysis. A device that performs impressively in a demonstration may still face difficult adoption economics if it requires extensive specialist support. Conversely, an improvement that reduces treatment adjustments or fits existing clinical workflows could have substantial practical value. This suggests that convenience deserves attention alongside technical performance. For a person using an implanted device, the relevant measure is the balance between benefit and burden. Reliability, manageable follow-up, and continued access to support can be as consequential as a headline specification. Medtronic offers exposure to brain-responsive medicine. For investors interested in this direction of healthcare, Medtronic offers a publicly traded company with an existing neurostimulation business and an approved adaptive product. MDT price chart. The investment connection is direct: BrainSense combines sensing, implanted hardware, and therapy adjustment within the company's DBS platform. Investors can evaluate adoption and commercial execution rather than relying entirely on forecasts about experimental technologies. However, Medtronic is a diversified medical-device company. Its share performance reflects a much broader business than brain stimulation. Exposure to neurotechnology therefore comes alongside other product markets, operating costs, competitive pressures, and execution risks. Useful questions include whether adaptive features encourage adoption, how effectively the company supports clinicians, and whether patient benefits justify the costs of treatment. An approved product establishes an important commercial foundation; it does not guarantee rapid growth or an attractive valuation.

State Investment Council invests $120 million in Lightspeed, despite activists' objections. In total, the SIC approved $1.07 billion in investments on Tuesday Published October 30, 2026 - 12:55 p.m. Modified October 30, 2026 - 2:20 p.m. The council overseeing New Mexico's sovereign wealth fund approved $1.07 billion in new investments on Tuesday, including $120 million in funds managed by the venture capital firm Lightspeed. The New Mexico State Investment Council committed $100 million to the Silicon Valley firm's AI Renaissance Fund and $20 million to a related co-investment vehicle. The investments drew opposition from activist groups, which argued they would expand the SIC's stake in firms owned by tech billionaire Elon Musk. But the SIC's new investments are not linked to Musk, State Investment Officer Jon Clark said in an interview. The AI Renaissance Fund, which has not yet begun its investment period, will use a strategy focused on buying out established companies in the service sector, then streamlining their operations with artificial intelligence. Other Lightspeed funds have invested in Musk's companies, including xAI and Neuralink, according to the firm's website. The SIC has previously invested in nine Lightspeed funds and has $160 million in active investments. However, the SIC is contractually prohibited from sharing details about individual investors' portfolios, spokesperson Charles Wollman wrote in an email. Opponents of the Lightspeed investment, including the activist groups Concerned Citizens for Nuclear Safety and Common Ground Rising, also cited the firm's backing of Castelion Corp., a defense startup building a 1,000-acre solid rocket motor manufacturing site in Sandoval County. "Many managers have multiple strategies and different funds - completely separate from each other," Clark said. "There is no tie whatsoever between this Lightspeed investment and Castelion." For Elaine Cimino, the leader of Common Ground Rising, the specifics of the SIC's latest commitment aren't the point. "The problem is Lightspeed," she said. Isaac Kim, a Lightspeed partner, said at Tuesday's SIC meeting that the fund has already raised more than $750 million, exceeding its initial target. Founded in 2000, Lightspeed said last year that it manages more than $50 billion in assets. The firm was the largest investor in Anthropic's $3.5 billion Series E financing round and has also backed Anduril, Grubhub and Snap Inc. New Mexico's sovereign wealth fund, which held less than $50 billion in assets when Clark took its helm nearly three years ago, is now worth $75.8 billion. Facing an influx of money, the SIC has scrambled to meet its portfolio targets. The SIC has placed most incoming revenue in public equity and core bonds, which are relatively liquid and simpler to invest in. But the fund has lagged behind its goals for private market investments, which require more vetting and longer negotiations, Clark said. Tuesday's investments are part of an ongoing effort to catch up. The SIC voted to establish a new relationship with Arcmont Asset Management, placing $150 million in the Arcmont Capital Solutions Fund III, a European private debt fund. Another $100 million went to the Advent Mid-Market Private Equity SCSP, which focuses on buyouts of European and North American firms in the consumer, healthcare, industrial, and business and financial services sectors. The SIC has made four previous commitments to Advent funds. The SIC also voted to re-up commitments to three funds. The state will invest $225 million in the Copenhagen Infrastructure Fund VI, which backs renewable energy development, and $125 million in a related co-investment vehicle. It will also invest $200 million in EQT Exeter Industrial Value Fund VII, a logistics and light industry fund and $400 million in the FPA Blue Chip Secure Value Fund VII, which focuses on multifamily housing. Established in 1958, the sovereign wealth fund invests revenue from New Mexico's taxes on oil and gas production, as well as leases and sales of public land and minerals. Some of the returns are distributed to support state services, including universities and early childhood education. Returns from the fund play an increasingly significant role in the state budget. With New Mexico's crude oil production booming - and gas prices spiking during the war in Iran - the fund is expected to generate $2.3 billion in distributions in fiscal year 2027. "Our projections are that by 2050, we will be supplying 37% of the state's general fund revenue," Clark said. "That significantly exceeds all corporate and personal income tax combined, and it also exceeds all sales taxes." Tilly Robinson covers the economy and healthcare for the Journal. You can reach her at [email protected].